Abstract-Neuronal reuptake (uptake-1) constitutes the main route of inactivation of the sympathetic neurotransmitter norepinephrine in the heart and therefore contributes importantly to cardiac sympathetic neuroeffector function. In laboratory animals and in vitro preparations, half saturation of the transporter occurs at norepinephrine concentrations of 0.1 to 1 mol/L. This study addressed whether endogenous norepinephrine can attain high enough plasma concentrations in humans to inhibit cardiac uptake-1. Patients with increased plasma norepinephrine levels due to pheochromocytoma were assessed by 6-[ 18 F]fluorodopamine positron emission tomography. Above an antecubital venous plasma concentration of 3 nmol/L (Ϸ500 pg/mL), left ventricular myocardial 6-[18 F]fluorodopamine-derived radioactivity varied inversely with the logarithm of the plasma norepinephrine concentration (rϭϪ0.77, PϽ0.0001). Reduction of plasma norepinephrine levels by treatment of the pheochromocytoma increased myocardial 6-[18 F]fluorodopamine-derived radioactivity. At sufficiently high plasma concentrations, endogenous norepinephrine can compete with sympathetic imaging agents for uptake-1. The results call for caution in drawing quantitative conclusions about uptake-1 in the setting of high circulating concentrations of endogenous norepinephrine. Key Words: heart Ⅲ norepinephrine Ⅲ pheochromocytoma Ⅲ radiography N euronal reuptake of the sympathetic neurotransmitter norepinephrine through the membrane norepinephrine transporter 1-3 (also known as uptake-1) is a key determinant of inactivation of norepinephrine in the heart and, therefore, of cardiac sympathetic neuroeffector function. Cardiac sympathetic neuroimaging, using radiolabeled sympathomimetic amines such as 123 I-or 131 I-metaiodobenzylguanidine (MIBG) or catecholamines such as 6-[18 F]fluorodopamine, depends on uptake of the imaging agent into sympathetic nerves through the cell membrane norepinephrine transporter.Pheochromocytoma tumor cells also express the cell membrane norepinephrine transporter. Scintigraphy or singlephoton emission-computed tomography after injection of radioiodinated MIBG or positron emission tomography after injection of 6-[18 F]fluorodopamine aids diagnostic localization of pheochromocytoma. 4 Preclinical studies dating back to the 1960s have demonstrated saturability of uptake-1, with a K m in the range of 0.1 to 1 mol/L. 5,6 Since plasma norepinephrine levels in humans normally average about 3 nmol/L, increasing by at most 10-to 20-fold in extreme situations, one might presume that circulating norepinephrine would exert little impact on the efficiency of uptake-1. Reports that patients with high circulating norepinephrine concentrations due to pheochromocytoma can have decreased myocardial MIBG-derived radioactivity, however, have called this view into question. [7][8][9] In the present study, we show that myocardial 6-[18 F]fluorodopamine-derived radioactivity decreased when plasma norepinephrine levels were markedly elevated in patients with pheoch...